City of Hope's PANXEON Blood Test Shows 87% Accuracy in Early Pancreatic Cancer Detection — City of Hope

Event summary

City of Hope's PANXEON blood test demonstrated 87% sensitivity in detecting stage 1 and 2 pancreatic cancer in a study of 1,800 patients across the US, Europe, and Asia.
The test combines three biomarkers (circulating microRNAs, exosomal microRNAs, and CA19-9 protein) with AI analysis to generate a risk score.
False-positive rates were 3% in low-risk groups and 16% in high-risk groups, with the test also detecting high-grade dysplasia 64% of the time.
The study was published in Nature Medicine on September 16, 2026, supported by NIH/NCI and Italian Association for Cancer Research grants.

The big picture

City of Hope's PANXEON test represents a significant advancement in early pancreatic cancer detection, addressing a critical unmet need where current diagnostic methods often fail. The test's multi-biomarker approach and AI integration position it as a potential game-changer in oncology diagnostics, with implications for improving survival rates through earlier intervention. This development comes as the cancer diagnostics market increasingly shifts toward liquid biopsy technologies and precision medicine approaches.

What we're watching

Commercialization Path: Whether Biocartis will exercise its option to acquire PANXEON and the timeline for potential regulatory approval and market launch.
Clinical Validation: The pace at which additional validation studies will be conducted in diverse patient populations to confirm these results.
Competitive Positioning: How PANXEON will differentiate itself from other emerging early detection technologies in the pancreatic cancer space.